Related Experiment Videos
Invasive Aspergillus infections in hematologic malignancy patients
Sofia Perea1, Thomas F Patterson
1Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, 78229-3900, USA.
Abstract:
The incidence of invasive Aspergillus (IA) infections in patients with hematologic malignancies continues to increase. The most common species include Aspergillus fumigatus (approximately 90% of cases), A. flavus, A. niger, A. terreus, and A. nidulans. Most infections involve the pulmonary parenchyma, though systemic dissemination of the fungus from a primary pulmonary focus or the paranasal sinuses after hyphal invasion into blood vessels is frequent. Early diagnosis and initiation of appropriate antifungal therapy has been shown to improve the prognosis of patients afflicted with this condition. The definitive diagnosis of IA is based on showing the hyphal invasion in tissue specimens together with a positive culture for Aspergillus species from the same specimen. The detection of circulating fungal antigens and DNA seems to be a promising, rapid, and sensitive diagnostic tool for early diagnosis of aspergillosis. The current antifungals available for the treatment of IA include amphotericin B deoxycholate and lipid formulations, itraconazole and caspofungin acetate. New investigational antifungal drugs include the triazoles voriconazole, posaconazole and ravuconazole, liposomal nystatin, and 2 echinocandin derivatives (anidulafungin [VER-002] and micafungin [FK463]). Preventive measures include reduction of environmental exposure of patients from sources of infection and anti-fungal prophylaxis. Specialized air-handling systems capable of excluding Aspergillus spores, such as high-efficiency particulate air (HEPA) filtration with or without laminar air flow ventilation has proven to be very efficacious. Targeted antifungal prophylaxis for hematologic patients who are at high risk for developing invasive fungal infections is not currently standardized.
Insights
Invasive Aspergillus infections are rising in hematologic malignancy patients. Early diagnosis and new antifungal treatments are crucial for improving outcomes in aspergillosis.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Invasive Aspergillus infections (IA) pose a growing threat to patients with hematologic malignancies.
- Aspergillus fumigatus is the most common causative species, leading to pulmonary and systemic infections.
Purpose of the Study:
- To review the current landscape of invasive aspergillosis in hematologic patients.
- To discuss diagnostic strategies, available and investigational treatments, and preventive measures.
Main Methods:
- Literature review of invasive aspergillosis diagnosis and treatment.
- Analysis of current and emerging antifungal therapies and preventive strategies.
Main Results:
- Definitive diagnosis relies on tissue invasion and positive cultures; circulating fungal antigens and DNA offer promising rapid detection.
- Current treatments include amphotericin B, itraconazole, and caspofungin; new agents like voriconazole and posaconazole are under investigation.
- Preventive measures involve environmental control (HEPA filtration) and antifungal prophylaxis, though the latter is not standardized for high-risk patients.
Conclusions:
- Prompt diagnosis and appropriate antifungal therapy significantly improve prognosis for IA patients.
- A combination of environmental controls, effective diagnostics, and optimized antifungal strategies is essential for managing IA in this vulnerable population.